Grading in Superficial Bladder Cancer. (1) Morphological Criteria

Authors

  • R. P. E. PAUWELS,

    Corresponding author
    1. Department of Urology, St Maartens Gasthuis, Venlo, The Netherlands
      Department of Urology, St Maartens Gasthuis, Tegelseweg 210, 5912 BL Venlo, The Netherlands
    Search for more papers by this author
    • 2

      R. P. E. Pauwels, MD, Urologist, St Maartens Gasthuis, Venlo.

  • R. F. M. SCHAPERS,

    1. Department of Urology, St Maartens Gasthuis, Venlo, The Netherlands
    Search for more papers by this author
    • 3

      R. F. M. Schapers, MD, Clinical pathologist, St Maartens Gasthuis, Venlo.

  • A. W. G. B. SMEETS,

    1. Department of Urology, St Maartens Gasthuis, Venlo, The Netherlands
    Search for more papers by this author
    • 4

      A. W. G. B. Smeets, Cytogeneticist, Clinical Laboratory, Venray.

  • F. M. J. DEBRUYNE,

    1. Department of Urology, St Maartens Gasthuis, Venlo, The Netherlands
    Search for more papers by this author
    • 5

      F. M. J. Debruyne, MD, Professor, Department of Urology, Radboud Hospital, Catholic University, Nijmegen.

  • J. P. M. GERAEDTS

    1. Department of Urology, St Maartens Gasthuis, Venlo, The Netherlands
    Search for more papers by this author
    • 6

      J. P. M. Geraedts, Professor, Department of Genetics and Cell Biology, State University Limburg, Maastricht.


Department of Urology, St Maartens Gasthuis, Tegelseweg 210, 5912 BL Venlo, The Netherlands

Abstract

Summary— In a prospective study on the grading of superficial papillary neoplasms of the bladder a distinction was made between tumours showing only increased cellularity without appreciable cellular and nuclear deviation (grade l), tumours showing slight cellular variation (grade 2a), and tumours showing clear cytological deviation and a tendency to lose normal polarity (grade 2b).

Ninety-one patients with a superficial tumour were followed up for a mean of 24 months. Grade 2a tumours recurred later and in fewer patients than grade 2b tumours. Progression was seen in 4% of grade 2a tumours and in 33% of grade 2b carcinomas. Adapting our results to the WHO grading system, we suggest that all tumours in this study defined as grades 1 and 2a should be classified as low grade and tumours defined as grade 2b should be classified as intermediate grade.

Ancillary